1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
FEATURED COMPANIES
- AbbVie
- F. Hoffmann-La Roche
- Gilead
- Vertex Pharmaceuticals
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
About Cystic Fibrosis Therapeutics
CF is a genetic disorder that mostly affects the lungs and sometimes other parts of the body such as the liver, pancreas, intestines, and the kidneys. The disease is inherited in an autosomal recessive manner. It is due to mutations caused in both the copies of the gene for the CFTR protein.
The analysts forecast the global cystic fibrosis therapeutics market to grow at a CAGR of 17.28% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global cystic fibrosis therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
The report, Global Cystic Fibrosis Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
Market drivers
Market challenges
Market trends
Key questions answered in this report
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
CF is a genetic disorder that mostly affects the lungs and sometimes other parts of the body such as the liver, pancreas, intestines, and the kidneys. The disease is inherited in an autosomal recessive manner. It is due to mutations caused in both the copies of the gene for the CFTR protein.
The analysts forecast the global cystic fibrosis therapeutics market to grow at a CAGR of 17.28% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global cystic fibrosis therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
The report, Global Cystic Fibrosis Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- AbbVie
- Gilead
- F. Hoffmann-La Roche
- Vertex Pharmaceuticals
Market drivers
- Improved diagnostic technologies
- For a full, detailed list, view the full report
Market challenges
- Drug discontinuation
- For a full, detailed list, view the full report
Market trends
- Strategic collaborations
- For a full, detailed list, view the full report
Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AbbVie
- F. Hoffmann-La Roche
- Gilead
- Vertex Pharmaceuticals
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORTPART 03: RESEARCH METHODOLOGYPART 09: CUSTOMER LANDSCAPEPART 11: DECISION FRAMEWORK
PART 04: INTRODUCTION
PART 05: MARKET LANDSCAPE
PART 06: MARKET SIZING
PART 07: FIVE FORCES ANALYSIS
PART 08: MARKET SEGMENTATION BY DRUG CLASS
PART 10: REGIONAL LANDSCAPE
PART 12: DRIVERS AND CHALLENGES
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
PART 15: VENDOR ANALYSIS
PART 16: APPENDIX
List of Exhibits
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AbbVie
- F. Hoffmann-La Roche
- Gilead
- Vertex Pharmaceuticals
New Report Released: - Global Cystic Fibrosis Therapeutics Market 2018-2022
The author of the report recognizes the following companies as the key players in the global cystic fibrosis therapeutics market: AbbVie, Gilead, F. Hoffmann-La Roche, and Vertex Pharmaceuticals.
Commenting on the report, an analyst from the research team said: “One trend in the market is strategic collaborations. M&A are usually intended to enhance a company's product portfolio and increase the acquiring company's market penetration. Established pharmaceutical companies acquire late-stage products from small companies, where the efficacy of products has already been demonstrated, thereby cutting down on initial R&D expenditure.”
According to the report, one driver in the market is improved diagnostic technologies. CF is a genetically inherited disease. Several diagnostic tests are available to detect the disease. Some of the popular methods of diagnosis are antenatal testing, carrier testing, and other tests such as genetic tests and sweat tests. Growing investment in and awareness about genetic diseases are expected to lead to improved diagnostic technologies, which will drive the growth of the market.
Further, the report states that one challenge in the market is drug discontinuation. Discontinuation of drugs from the development stage or from the market after their launch is a major challenge for investors and drug manufacturers. The discontinuation of drugs from the late-stage development or after approval due to reasons such as safety concerns leads to a significant financial loss for investors because of the high R&D and marketing costs involved in the process of drug development.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The author of the report recognizes the following companies as the key players in the global cystic fibrosis therapeutics market: AbbVie, Gilead, F. Hoffmann-La Roche, and Vertex Pharmaceuticals.
Commenting on the report, an analyst from the research team said: “One trend in the market is strategic collaborations. M&A are usually intended to enhance a company's product portfolio and increase the acquiring company's market penetration. Established pharmaceutical companies acquire late-stage products from small companies, where the efficacy of products has already been demonstrated, thereby cutting down on initial R&D expenditure.”
According to the report, one driver in the market is improved diagnostic technologies. CF is a genetically inherited disease. Several diagnostic tests are available to detect the disease. Some of the popular methods of diagnosis are antenatal testing, carrier testing, and other tests such as genetic tests and sweat tests. Growing investment in and awareness about genetic diseases are expected to lead to improved diagnostic technologies, which will drive the growth of the market.
Further, the report states that one challenge in the market is drug discontinuation. Discontinuation of drugs from the development stage or from the market after their launch is a major challenge for investors and drug manufacturers. The discontinuation of drugs from the late-stage development or after approval due to reasons such as safety concerns leads to a significant financial loss for investors because of the high R&D and marketing costs involved in the process of drug development.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- AbbVie
- Gilead
- F. Hoffmann-La Roche
- Vertex Pharmaceuticals
Note: Product cover images may vary from those shown
